{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:36Z","timestamp":1788174576220,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100115","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T06:08:07Z","timestamp":1746943687000},"page":"100115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1\/2 study"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4620","authenticated-orcid":false,"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don Ambrose","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2025.100115_bib1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.bneo.2025.100115_bib2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100115_bib3","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bneo.2025.100115_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.bneo.2025.100115_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100115_bib6","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2025.100115_bib7","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100115_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2025.100115_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bneo.2025.100115_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106640","article-title":"Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy","volume":"109","author":"Hunter","year":"2021","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.bneo.2025.100115_bib11","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1038\/s41375-021-01227-z","article-title":"Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia","volume":"35","author":"Eisenwort","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bneo.2025.100115_bib12","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bneo.2025.100115_bib13","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1182\/bloodadvances.2020002415","article-title":"Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia","volume":"4","author":"Mangaonkar","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bneo.2025.100115_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100115_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41375-018-0279-6","article-title":"Histone deacetylase inhibitor targets CD123\/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia","volume":"33","author":"Yan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2025.100115_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2019.05.002","article-title":"CD123 CAR T cells for the treatment of myelodysplastic syndrome","volume":"74","author":"Stevens","year":"2019","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100115_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bneo.2025.100115_bib18","first-page":"44","article-title":"Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm","volume":"109","author":"Luskin","year":"2023","journal-title":"Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100115_bib19","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2025.100115_bib20","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2025.100115_bib21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100115_bib22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100115_bib23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3324\/haematol.2019.218677","article-title":"Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia","volume":"105","author":"Woo","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bneo.2025.100115_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100115_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/bloodadvances.2024014467","article-title":"Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response","volume":"9","author":"Ismail","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2025.100115_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-05-500413","article-title":"BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells","volume":"122","author":"Boiocchi","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2025.100115_bib27","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100115_bib28","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1182\/blood-2021-153475","article-title":"Outcomes of patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents","volume":"138","author":"Venugopal","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100115_bib29","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-021-01330-1","article-title":"Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia","volume":"35","author":"Renneville","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2025.100115_bib30","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2022.2056175","article-title":"Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation","volume":"63","author":"Mangaonkar","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100115_bib31","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood-2023-179688","article-title":"Lenzilumab in addition to azacitidine improves complete response rates in chronic myelomonocytic leukemia","volume":"142","author":"Hiwase","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100115_bib32","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(23)00367-8","article-title":"Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1\/2 study","volume":"11","author":"Bataller","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bneo.2025.100115_bib33","series-title":"Phase I\/II study of tagraxofusp in combination with decitabine for patients with myelomonocytic\/myeloproliferative neoplasm and high risk myelodysplastic syndrome. ClinicalTrials.gov identifier: NCT05038592","year":"2025"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:39:42Z","timestamp":1764121182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000500"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100115","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1\/2 study","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100165","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100115"}}